RecruitingNot ApplicableNCT07258914

Feasibility and Efficacy of rTMS in Depression in Patients With Autism Spectrum Disorder (ASD)

Feasibility and Efficacy of rTMS in Depression in Individuals With Autism Spectrum Disorder (ASD)


Sponsor

Hospital Center Guillaume Régnier

Enrollment

25 participants

Start Date

Dec 19, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Depression is a common complication of Autism Spectrum Disorder (ASD): it is four times more prevalent in people with ASD than in the general population. However, treating depression in people with ASD is complicated by the lack of guidelines. Antidepressants appear to be less effective and less well tolerated than in the general population. rTMS (repetitive transcranial magnetic stimulation) is a technique that stimulates the brain in a painless and non-invasive way. This technique is well tolerated and has very few side effects (headaches, fatigue). It is now used routinely in clinical practice to treat resistant depression, with satisfactory results. A few studies using rTMS in depression in people with ASD have shown encouraging results and avenues for improvement. It could therefore be interesting to conduct a therapeutic study with rTMS on depression in people with ASD, following the avenues for improvement proposed by previous studies. The main objective is to evaluate the effectiveness of rTMS in depressed patients with ASD by looking at changes in mood before and after treatment. The investigator will also look at the effects on executive and attentional functions and repetitive behaviors, as well as treatment tolerance.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether repetitive transcranial magnetic stimulation (rTMS) — a non-invasive brain stimulation technique using magnetic pulses — can help treat depression in adults who also have autism spectrum disorder (ASD). **You may be eligible if...** - You are between 18 and 65 years old - You have a confirmed diagnosis of ASD from a specialist - You are experiencing significant depression (MADRS score above 20) - Your current medications have been stable for at least one month before joining **You may NOT be eligible if...** - Your depression or psychiatric medications have changed recently - You have conditions that make rTMS unsafe (such as metal implants in the head, a history of seizures, or certain neurological conditions) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERrTMS

Patients receive 20 sessions of intermittent theta burst stimulation of the left CPFDL over 5 days (4 sessions of 10 minutes per day with a 50-minute interval between each session). The CPFDL is located using neuronavigation, which requires an MRI scan (without contrast agent injection) before the sessions.

OTHERrTMS treatment with intermittent Theta Burst (ITBS)

rTMS (iTBS) treatment with stimulation of the left dorsolateral prefrontal cortex (DLPFC). Localization is performed using neuronavigation. There are four 10-minute sessions per day, with a 50-minute interval between each session.


Locations(1)

Centre Hospitalier Guillaume Régnier

Rennes, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07258914


Related Trials